Limb Girdle Muscular Dystrophy (LGMD) Pipeline Assessment, 2023 | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies

February 28 03:23 2023
Limb Girdle Muscular Dystrophy (LGMD) Pipeline Assessment, 2023 | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 20+ key pharma and biotech companies are working on 25+ pipeline drugs in the Limb Girdle Muscular Dystrophy (LGMD) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

The Limb Girdle Muscular Dystrophy therapeutics dynamics are anticipated to evolve immensely in the coming years owing to the rise in the number of prevalent cases of Limb Girdle Muscular Dystrophy patients and the launch of new therapies in the market.

Limb Girdle Muscular Dystrophy Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Limb Girdle Muscular Dystrophy Market. 

The Limb Girdle Muscular Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Limb Girdle Muscular Dystrophy Pipeline Analysis

Limb Girdle Muscular Dystrophy Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Limb Girdle Muscular Dystrophy and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Limb Girdle Muscular Dystrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

 

Route of Administration

Limb Girdle Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Inhalation

  • Inhalation/Intravenous/Oral

  • Intranasal

  • Intravenous

  • Intravenous/ Subcutaneous

  • Oral

  • Oral/intranasal/subcutaneous

  • Parenteral

  • Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Antibody

  • Antisense oligonucleotides

  • Immunotherapy

  • Monoclonal antibody

  • Peptides

  • Protein

  • Recombinant protein

  • Small molecule

  • Stem Cell

  • Vaccine

 

Mechanism of Action (MOA) of the Emerging Pipeline Therapies

  • NF-kappa B inhibitors

  • Histidine-tRNA ligase modulators

  • Glycosylation stimulants

  • Integrin Stimulants 

  • Gene transference

 

Learn How the Ongoing Clinical & Commercial Activities will Affect the Limb Girdle Muscular Dystrophy Therapeutic Segment @

https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight

Limb Girdle Muscular Dystrophy Therapeutics Landscape

There are approx. 20+ key companies developing therapies for Limb Girdle Muscular Dystrophy. Currently, ML Bio Solutions is leading the therapeutics market with its Limb Girdle Muscular Dystrophy drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Limb Girdle Muscular Dystrophy (LGMD) Therapeutics Market Include:

  • Asklepios BioPharmaceutical

  • Atamyo Therapeutics

  • aTyr Pharma

  • BridgeBio Pharma

  • Catabasis Pharmaceutical

  • Edgewise Therapeutics

  • Hansa Biopharma

  • ML Bio Solutions

  • Sarepta Therapeutics

  • Strykagen

  • Vita Therapeutics

And many others

Limb Girdle Muscular Dystrophy Drugs Covered in the Report Include:

  • ATYR1940: aTyr Pharma

  • BBP-418: ML Bio Solutions

  • CAT-1004: Catabasis Pharmaceutical

  • LION-101: Asklepios BioPharmaceutical

  • SRP-9005: Sarepta Therapeutics

  • Stryka 516s: Strykagen

  • ATA-100: Atamyo Therapeutics

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Limb Girdle Muscular Dystrophy Current Treatment Patterns

4. Limb Girdle Muscular Dystrophy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Limb Girdle Muscular Dystrophy Late Stage Products (Phase-III)

7. Limb Girdle Muscular Dystrophy Mid-Stage Products (Phase-II)

8. Limb Girdle Muscular Dystrophy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Limb Girdle Muscular Dystrophy Discontinued Products

13. Limb Girdle Muscular Dystrophy Product Profiles

14. Key Companies in the Limb Girdle Muscular Dystrophy Market

15. Key Products in the Limb Girdle Muscular Dystrophy Therapeutics Segment

16. Dormant and Discontinued Products

17. Limb Girdle Muscular Dystrophy Unmet Needs

18. Limb Girdle Muscular Dystrophy Future Perspectives

19. Limb Girdle Muscular Dystrophy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight

 

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services and Solutions

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

view more articles

About Article Author